Newsroom

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Low Duration Global Government Bond UCITS ETF 09.01.2026 FGOV LN IE00BKS2X200 33,638.00 GBP 499,111.11 17.103  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust IPOX Europe Equity Opportunities UCITS ETF 09.01.2026 IPXE.IM IE00BFD26097 75,002.00 EUR 1,757,286.32 23.430  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Cloud Computing UCITS ETF 09.01.2026 CPQ IE00BFD2H405 8,800,002.00 USD 477,096,734.56 54.216  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Dow Jones Internet UCITS ETF 09.01.2026 FDNU IE00BG0SSC32 2,325,002.00 USD 86,325,528.29 37.129  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Europe Growth Strength UCITS ETF 09.01.2026 FTEG.LN IE0009F7UB30 50,002.00 EUR 1,045,680.63 20.913  ...

SAN DIEGO--(BUSINESS WIRE)--Mirador Therapeutics, Inc. (Mirador), a clinical-stage precision medicine company developing next-generation therapies for immune-mediated inflammatory and fibrotic diseases, today announced key clinical updates and corporate progress. I&I is the second-largest drug spend category in the U.S., yet millions of patients remain untreated or inadequately served by current therapies. Mirador is pioneering precision medicine approaches designed to overcome the efficacy...

LONDON--(BUSINESS WIRE)--  09-January-2026 Issue: Newday Funding Master Issuer Plc Series 2024-1 Class E RegS XS2768183332 Pursuant to our appointment as Agent for the above stated issue, please be advised of the following interest rate determination: Date From: 15-December-2025 Date To: 15-January-2026 Record Date: 14-January-2026 Value Date: 15-January-2026 Benchmark Rate: 3.84354% Margin: 4.8% Total Rate: 8.64354% Number of Days: 31 Day Count: Actual / 365L Interest Frequency: Monthly Total...

NEW YORK & TOKYO--(BUSINESS WIRE)--Nuvation Bio Inc. (NYSE: NUVB, Corporate Headquarters: New York, NY, CEO: David Hung, M.D., “Nuvation Bio”), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, and Eisai Co., Ltd (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”), a human-centered global leading research-based pharmaceutical company working in the neurology and oncology therapeutic areas, today announced an exclusive license and collaboration agree...

GURUGRAM, India & NEW YORK--(BUSINESS WIRE)--MakeMyTrip Limited plans to report its fiscal 2026 third quarter financial and operating results before markets open on Wednesday, January 21, 2026....

SOUTH SAN FRANCISCO, Calif. & LEIDEN, Netherlands--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced it has secured a site and signed a long-term lease for a new IDMO Smart Factory at Leiden Bio Science Park (LBSP) with Dura Vermeer Commercieel Vastgoed. The facility will serve as Cellares’ European headquarters and expand the company’s global manufacturing network with dedicated regional capacity. Cell therapy manufacturing is pa...